Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC

25 Oct 2020

Abstract excerpt

The myelocytomatosis oncogene (MYC) is an important driver in a subtype of pancreatic ductal adenocarcinoma (PDAC). However, MYC remains a challenging therapeutic target; therefore, identifying druggable synthetic lethal interactions in MYC-active PDAC may lead to novel precise therapies. First, to identify networks with hyperactive MYC, we profiled transcriptomes of established human cell lines, murine primary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Pancreatic and Hepatic Oncology Research
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33099868
DOI: 10.1002/1878-0261.12835

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYCPMID 33099868Read ↗

Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYCSemantic proximity Read ↗

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerSemantic proximity Read ↗

Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtypeSemantic proximity Read ↗

Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug RepurposingSemantic proximity Read ↗

Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2Semantic proximity Read ↗

Concepts to Target MYC in Pancreatic Cancer.Semantic proximity Read ↗

USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancerSemantic proximity Read ↗

Proteasome regulators in pancreatic cancerSemantic proximity Read ↗

The interaction between UBR7 and PRMT5 drives PDAC resistance to gemcitabine by regulating glycolysis and immune microenvironmentSemantic proximity Read ↗

Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapySemantic proximity Read ↗

MondoA mediates transcriptional coordination between the MYC network and the integrated stress response in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.